Sleep disturbances

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study

Nutrients.2023 Apr 18;15(8):1949. doi: 10.3390/nu15081949. Elisabeth Blüthner, Ulrich-Frank Pape, Frank Tacke, Sophie Greif PMID: 37111167 DOI: 10.3390/nu15081949 Abstract Background: Quality of life (QoL) data of chronic intestinal failure (cIF) patients treated with the GLP-2 analogue teduglutide are scarce. This study aims to analyze QoL changes over time in teduglutide-treated patients and compare the results to a matched non-treated cIF control […]

Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program

26. August 2022

ORIGINAL ARTICLE| VOLUME 51, P222-230, OCTOBER 2022 Sophie Greif, Sebastian Maasberg, Jan Wehkamp, Elisabeth Blüthner, Frank Tacke, Ulrich-Frank PapeDOI: https://doi.org/10.1016/j.clnesp.2022.08.027 Abstract Background & aims: Teduglutide is a Glucagon-like peptide-2 (GLP-2) agonist indicated for the treatment of patients with parenteral support (PS) dependent short bowel syndrome (SBS) with chronic intestinal failure (cIF). Its application is accompanied by a structured

Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program Weiterlesen »